Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2008

01.01.2008 | Original Article

The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns

verfasst von: N. Cenk Sayın, M. Tunç Canda, Nefize Ahmet, Sezer Arda, Necdet Süt, Füsun G. Varol

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study was designed to investigate the relationship between the second trimester maternal serum markers and adverse pregnancy outcomes in healthy newborns.

Materials and methods

A total of 749 women who delivered in our institution with complete follow up and second-trimester triple marker test data available were included in the study. Women with multiple pregnancies, chronic diseases, diabetes mellitus, obesity, smokers and infants with chromosomal and congenital abnormalities were excluded. Maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) and unconjugated estriol (uE3) values were investigated in our cohort who developed preeclampsia (n = 28), gestational diabetes (GM) (n = 69), preterm labor-birth (n = 100), oligohydramnios (n = 37) and macrosomia (n = 59) by using receiver operating characteristic (ROC) curve analysis, with chi-square and Pearson’s correlation tests.

Results

Women with uE3 ≤ 1.26 MoM (P = 0.001, AUC = 0.666), HCG > 1.04 MoM (P = 0.032, AUC = 0.599) or AFP ≤ 0.69 MoM (P = 0.049, AUC = 0.600) values significantly developed oligohydramnios. Also, macrosomic infants were observed in women who had HCG values > 0.86 MoM (P = 0.047, AUC = 0.578). Patients with HCG > 1.04 MoM (P = 0.04, AUC = 0.565) and uE3 ≤0.88 MoM (P = 0.049, AUC = 0.571) developed GDM. HCG levels ≥2.5 or ≥3 MoM were significantly associated with the development of oligohydramnios [P = 0.005; OR = 4 (95% CI: 1.7–9.7)], [P = 0.008; OR = 4.9 (95% CI: 1.7–13.7)], respectively. When women with adverse (n = 237) and normal (n = 512) outcomes were compared there were significant differences in maternal serum AFP (1.40 ± 0.84 vs. 1.23 ± 0.75 MoM, P = 0.006) and uE3 values (1.38 ± 1.42 vs. 1.45 ± 0.98 MoM, P = 0.001).

Conclusions

Serum estriol, AFP or HCG values in triple test results may be associated with development of oligohydramnios, gestational diabetes and macrosomia in women with healthy and normal appearing fetuses.
Literatur
1.
Zurück zum Zitat Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD (2005) Williams obstetrics. 22nd edn. McGraw-Hill, New York pp 313–340 Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD (2005) Williams obstetrics. 22nd edn. McGraw-Hill, New York pp 313–340
2.
Zurück zum Zitat Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP et al (1999) Second-trimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181:968–974PubMedCrossRef Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP et al (1999) Second-trimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181:968–974PubMedCrossRef
3.
Zurück zum Zitat Onderoglu LS, Kabukçu A (1997) Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynecol Obstet 56:245–249CrossRef Onderoglu LS, Kabukçu A (1997) Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynecol Obstet 56:245–249CrossRef
4.
Zurück zum Zitat Walter DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB (1996) The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816–822CrossRef Walter DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB (1996) The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816–822CrossRef
5.
Zurück zum Zitat Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA (2000) Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 182:589–594PubMedCrossRef Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA (2000) Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 182:589–594PubMedCrossRef
6.
Zurück zum Zitat Walton DL, Norem CT, Schoen EJ, Ray T, Colby CJ (1999) Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. N Engl J Med 341:2033–2036PubMedCrossRef Walton DL, Norem CT, Schoen EJ, Ray T, Colby CJ (1999) Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. N Engl J Med 341:2033–2036PubMedCrossRef
7.
Zurück zum Zitat Spencer K (2000) Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse pregnancy outcome. Prenat Diagn 20:652–656PubMedCrossRef Spencer K (2000) Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse pregnancy outcome. Prenat Diagn 20:652–656PubMedCrossRef
8.
Zurück zum Zitat American Diabetes Association (2003) Position statement: gestational diabetes mellitus. Diabetes Care 26(Suppl. 1):S103–S105 American Diabetes Association (2003) Position statement: gestational diabetes mellitus. Diabetes Care 26(Suppl. 1):S103–S105
9.
Zurück zum Zitat Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577PubMed Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577PubMed
10.
Zurück zum Zitat Wenstrom KD, Owen J, Boots LR, Dubard MB (1994) Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 171:1038–1041PubMed Wenstrom KD, Owen J, Boots LR, Dubard MB (1994) Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 171:1038–1041PubMed
11.
Zurück zum Zitat Bernstein IM, Bart RA, Miller R, Capeless EL (1992) Elevated maternal serum alpha-fetoprotein: association with placental sonolucencies, fetomaternal hemorrhage, vaginal bleeding and pregnancy outcome in the absence of fetal anomalies. Obstet Gynecol 79:71–74PubMed Bernstein IM, Bart RA, Miller R, Capeless EL (1992) Elevated maternal serum alpha-fetoprotein: association with placental sonolucencies, fetomaternal hemorrhage, vaginal bleeding and pregnancy outcome in the absence of fetal anomalies. Obstet Gynecol 79:71–74PubMed
12.
Zurück zum Zitat Huerta-Enochian G, Katz W, Erfurth S (2001) The association of abnormal α-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 184:1549–1553PubMedCrossRef Huerta-Enochian G, Katz W, Erfurth S (2001) The association of abnormal α-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 184:1549–1553PubMedCrossRef
13.
Zurück zum Zitat Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E (2003) Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 110:12–15PubMedCrossRef Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E (2003) Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 110:12–15PubMedCrossRef
14.
Zurück zum Zitat Boyd PA (1992) Why might maternal serum AFP be high in pregnancies in which the fetus is normally formed? Br J Obstet Gynaecol 99:93–95PubMed Boyd PA (1992) Why might maternal serum AFP be high in pregnancies in which the fetus is normally formed? Br J Obstet Gynaecol 99:93–95PubMed
15.
Zurück zum Zitat Kıran TSU, Bethel J, Bhal PS (2005) Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25:253–256PubMedCrossRef Kıran TSU, Bethel J, Bhal PS (2005) Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25:253–256PubMedCrossRef
16.
Zurück zum Zitat Berkeley AS, Killackey MA, Cederqvist LL (1983) Elevated maternal serum α-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 146:859–861PubMed Berkeley AS, Killackey MA, Cederqvist LL (1983) Elevated maternal serum α-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 146:859–861PubMed
17.
Zurück zum Zitat Boyd PA, Keeling JW (1986) Raised maternal serum α-fetoprotein in the absence of fetal abnormality-placental founding: a quantitative morphometric study. Prenat Diagn 6:369–373PubMedCrossRef Boyd PA, Keeling JW (1986) Raised maternal serum α-fetoprotein in the absence of fetal abnormality-placental founding: a quantitative morphometric study. Prenat Diagn 6:369–373PubMedCrossRef
18.
Zurück zum Zitat Luckas MJM, Sandland R, Hawe J, Neilson JP, McFadyen IR, Meekins JW (1998) Fetal growth retardation and second trimester maternal serum human chorionic gonadotropin levels. Placenta 19:143–147PubMedCrossRef Luckas MJM, Sandland R, Hawe J, Neilson JP, McFadyen IR, Meekins JW (1998) Fetal growth retardation and second trimester maternal serum human chorionic gonadotropin levels. Placenta 19:143–147PubMedCrossRef
19.
Zurück zum Zitat Lepage N, Chitayat D, Kingdom J, Huang T (2003) Association between second-trimester isolated high maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 188:1354–1359PubMedCrossRef Lepage N, Chitayat D, Kingdom J, Huang T (2003) Association between second-trimester isolated high maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 188:1354–1359PubMedCrossRef
20.
Zurück zum Zitat Ashour AM, Lieberman ES, Wilkins Haug LE, Repke JT (1997) The value of elevated second-trimester β-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol 176:438–442PubMedCrossRef Ashour AM, Lieberman ES, Wilkins Haug LE, Repke JT (1997) The value of elevated second-trimester β-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol 176:438–442PubMedCrossRef
21.
Zurück zum Zitat Summers A, Huang T, Meier C, Wyatt PR (2003) The implications of a false positive second-trimester serum screen for Down syndrome. Obstet Gynecol 101:1301–1306PubMedCrossRef Summers A, Huang T, Meier C, Wyatt PR (2003) The implications of a false positive second-trimester serum screen for Down syndrome. Obstet Gynecol 101:1301–1306PubMedCrossRef
22.
Zurück zum Zitat Towner D, Gandhi S, El Kady D (2006) Obstetrics outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 194:1676–1682PubMedCrossRef Towner D, Gandhi S, El Kady D (2006) Obstetrics outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 194:1676–1682PubMedCrossRef
23.
Zurück zum Zitat Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M (1992) The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 80:83–86PubMed Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M (1992) The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 80:83–86PubMed
24.
Zurück zum Zitat Liu DF, Dickerman LH, Redline RW (1999) Pathological findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. Am J Clin Pathol 111:209–215PubMed Liu DF, Dickerman LH, Redline RW (1999) Pathological findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. Am J Clin Pathol 111:209–215PubMed
25.
Zurück zum Zitat Sayin NC, Varol FG, Duran R, Acunas B, Kurt I (2007) Perinatal outcome in women screened for gestational diabetes mellitus with normal or with one elevated glucose tolerance test value. J Turkish German Gynecol Assoc 8:38–43 Sayin NC, Varol FG, Duran R, Acunas B, Kurt I (2007) Perinatal outcome in women screened for gestational diabetes mellitus with normal or with one elevated glucose tolerance test value. J Turkish German Gynecol Assoc 8:38–43
26.
Zurück zum Zitat Kowalczyk TD, Cabaniss ML, Cusmano L (1998) Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 91:396–400PubMedCrossRef Kowalczyk TD, Cabaniss ML, Cusmano L (1998) Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 91:396–400PubMedCrossRef
27.
Zurück zum Zitat Kim SY, Kim SK, Lee JS, Kim IK, Lee K (2000) The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down’s syndrome. Yonsei Med J 41:226–229PubMed Kim SY, Kim SK, Lee JS, Kim IK, Lee K (2000) The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down’s syndrome. Yonsei Med J 41:226–229PubMed
28.
Zurück zum Zitat Isouard G (1979) Measurement of serum levels of oestriol and human placental lactogen in the management of preeclamptic pregnancies. Med J Aust 2:401–404PubMed Isouard G (1979) Measurement of serum levels of oestriol and human placental lactogen in the management of preeclamptic pregnancies. Med J Aust 2:401–404PubMed
29.
Zurück zum Zitat Goodwin TM (1999) A role for estriol in human labor, term and preterm. Am J Obstet Gynecol 180:208–213CrossRef Goodwin TM (1999) A role for estriol in human labor, term and preterm. Am J Obstet Gynecol 180:208–213CrossRef
30.
Zurück zum Zitat Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA et al, for the FASTER Trial Research Consortium (2005) Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260–267PubMed Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA et al, for the FASTER Trial Research Consortium (2005) Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260–267PubMed
31.
Zurück zum Zitat Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ (1995) Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers. Obstet Gynecol 86:255–258PubMedCrossRef Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ (1995) Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers. Obstet Gynecol 86:255–258PubMedCrossRef
32.
Zurück zum Zitat Salafia CM, Silberman C, Herrerra NE, Mahoney MJ (1988) Placental pathology at term associated with elevated midtrimester maternal serum AFP concentration. Am J Obstet Gynecol 158:1064–1066PubMed Salafia CM, Silberman C, Herrerra NE, Mahoney MJ (1988) Placental pathology at term associated with elevated midtrimester maternal serum AFP concentration. Am J Obstet Gynecol 158:1064–1066PubMed
Metadaten
Titel
The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns
verfasst von
N. Cenk Sayın
M. Tunç Canda
Nefize Ahmet
Sezer Arda
Necdet Süt
Füsun G. Varol
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2008
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-007-0421-6

Weitere Artikel der Ausgabe 1/2008

Archives of Gynecology and Obstetrics 1/2008 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.